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Abstract
Aims: In a population at risk for type 2 diabetes (T2DM), we assessed early physical and metabolic
markers that predict progression from normal to impaired glucose tolerance (IGT) and T2DM.
Methods: A total of 388 individuals (22% male, age 46 + 11 years) at risk for T2DM were
randomized to Standard (n = 182) or Intervention (n = 206) care and evaluated at baseline and 5
annual follow-up visits, including blood pressure, BMI, A1C, lipids, urine albumin/creatinine ratio,
VO2max, fasting glucose, insulin and C-peptide. The Standard group received results of annual lab
tests and quarterly newsletters, while the Intervention group received quarterly newsletters and
detailed discussions of lab results, routine self-directed activities, semi-annual group meetings and
monthly telephone calls for ongoing support.
Results: Overall, 359 (93%) returned for at least one follow-up visit and 272 (70%) completed the
final 5-year assessment. Return rates, changes in measures and incidence of IGT/T2DM were
similar between groups. Low cardiorespiratory fitness (VO2max) was the most prevalent baseline
abnormality. A1C and BMI were significant predictors of IGT/T2DM after controlling for other
factors. The risk of IGT/T2DM within 5 years was 17.16 (95% CL: 6.169, 47.736) times greater for
those with baseline A1C>=5.8% as compared to those <5.8% (p < 0.0001).
Conclusion: Baseline A1C>=5.8% was a significant predictor of IGT/T2DM within 5 years in a
population at high risk for T2DM. A1C is routinely performed among patients with diabetes,
however these data and other evidence suggest that it may also be a useful tool for risk assessment
and screening.
Introduction
Diabetes is a chronic disease affecting 171 million of peo-
ple in the world [1]. The total cost of care for diabetes and
its associated complications in 2002 was estimated to be
$132 billion [2]. It is estimated that by the time individu-
als are diagnosed with type 2 diabetes (T2DM), they have
had abnormal glucose levels for approximately 10-12
years [3,4]. At the time of diagnosis, as many as 10 to 20%
of individuals already has early diabetes complications
due to years of undetected hyperglycemia [3,5,6]. Early
diagnosis and aggressive treatment aimed at normalizing
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glycemic levels can minimize the risk of microvascular
and macrovascular complications.
Increasing evidence supports the use of interventions that
permit changes in diet and physical activity or use of phar-
macological treatment to prevent or delay T2DM. These
findings provide an impetus for wider implementation of
preventive approaches and support the need for effective,
early screening of patients at risk. Early markers for diabe-
tes risk may identify individuals who are best to target for
interventions aimed at delaying or preventing the onset of
clinical disease.
One challenge in diabetes prevention is to identify per-
sons at risk who will benefit from various interventions. It
is important to determine what risk factors are associated
with the development of impaired glucose tolerance
(IGT) and type 2 diabetes in order to identify specific pop-
ulations for intervention efforts. The current study
assessed the efficacy of a community diabetes prevention
program on the development of IGT or T2DM in high risk
individuals at a relatively early stage of the disease, and
evaluated the potential for several markers of diabetes risk
to predict the development of IGT or T2DM in individuals
at risk.
Patients and methods
Study Population
Risk assessment was performed using a tool developed to
identify those at risk for T2DM. The specific risk assess-
ment tool used included questions derived from the ADA
diabetes screening questionnaire [7] and included family
history of diabetes, body weight > 20% over maximum
ideal weight, a history of diabetes during pregnancy or
having had a baby over 9 pounds, sedentary lifestyle, and
additional questions related to the metabolic syndrome
(hypertension, dyslipidemia and race/ethnicity). The
questionnaire was distributed to the community through
the mail, clinics, hospitals and pharmacies, and through
local television and public radio by request.
Subjects were eligible for enrollment if they met the fol-
lowing criteria: age 20 to 65 years and family history of
diabetes or history of gestational diabetes, or presence of
at least one and up to three risk factors for T2DM (obesity,
hypertension, dyslipidemia, fasting hyperglycemia) but
without all four of these high risk characteristics. Subjects
were excluded if they reported having no risk factors, or
reported either low activity level or race/ethnicity alone as
the only risk factor. In addition, those who were found to
have T2DM at baseline were excluded from the trial, as the
objective was to target intervention efforts early in the dis-
ease process prior to onset of clinical disease.
A total of 1,769 individuals completed the risk assessment
questionnaire. Of this group, 1,423 (80%) reported at
least one risk factor for type 2 diabetes. Of the 466 who
agreed to participate in the study, 418 qualified and com-
pleted baseline screening (28 individuals chose to with-
draw consent before enrollment, 12 were found to have
type 2 diabetes prior to enrollment and 8 had medical
conditions that excluded them from participation).
While individuals with IGT were eligible to participate in
this study, for the purposes of this report (which considers
IGT an endpoint) subjects with baseline IGT were
excluded from the analysis. In addition, although enroll-
ment took place prior to the revised ADA criteria for type
2 diabetes [8], our analysis applies the revised diagnostic
criteria for the classification of IGT and T2DM at all time
points in the study. A total of 388 of the original cohort of
418 were included in the current analysis (30 individuals
were excluded due to the presence of IGT or T2DM when
the revised ADA criteria were applied retrospectively to
baseline measures).
Randomization
All individuals enrolled in the trial completed baseline
laboratory tests and physical assessment, and received
written information regarding healthy eating, physical
activity and stress management [9]. Subjects were rand-
omized to either the Standard (n = 182) or Intervention (n
= 206) group. The Standard group received quarterly
newsletters with general information about the impor-
tance of healthy eating and physical activity, while the
Intervention group received newsletters with more spe-
cific information including methods for goal setting,
stress management and establishing/maintaining healthy
eating patterns, and strategies to increase physical activity.
In addition to quarterly newsletters, the Intervention
group received personalized interventions based on each
individual's readiness to make lifestyle changes. The Inter-
vention group was offered additional semi-annual group
education/motivation meetings, self-directed activities,
and individual telephone calls each month from trained
volunteer dietetic students to offer ongoing support. The
goal of the Intervention was to provide participants with
information, motivation and support to make healthy eat-
ing, physical activity and stress management changes.
Subjects in both the Standard and Intervention group
received annual laboratory, physical, health risk, psycho-
social and nutrition assessments. Results of physical
measures and lab tests were discussed in detail with those
in the Intervention group, while the Standard group par-
ticipants received a summary without detailed discussion.
In addition, individuals in the Intervention group set per-
sonal behavioral goals with the assistance of study staff,
while those in the Standard group did not.
Physical and Laboratory Assessments
The physical assessment evaluated BMI, waist/hip ratio,
blood pressure (sitting), and fitness level (as measured byDiabetology & Metabolic Syndrome 2009, 1:5 http://www.dmsjournal.com/content/1/1/5
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VO2max), defined as mL of oxygen consumed per kg body
weight per minute (mg/kg/min) during a bicycle ergom-
eter exercise tolerance test (Medgraphics, St. Paul, Minne-
sota). CVD risk category (Acceptable, Moderate or High
Risk) was assigned to each patient based on VO2max score
using age and gender-specific criteria by Cooper [10] and
adapted by Park Nicollet Medical Foundation (Minneap-
olis, MN) for bicycle testing. All subjects completed fast-
ing plasma glucose (FPG) determination, and those with
FPG of 110 mg/dL or greater underwent a 75 g oral glu-
cose tolerance test (OGTT). In addition, A1C (standard-
ized according to DCCT), fasting lipid fractionation (total
cholesterol, HDL-cholesterol, triglycerides and calculated
LDL-cholesterol), fasting insulin levels, fasting serum C-
peptide and albumin/creatinine (A/C) ratio were
obtained. The calculation of HOMA-IR was performed
using the homeostasis model assessment of Matthews, et
al [11].
Statistical Analysis
Descriptive statistics were calculated for all variables at
baseline and at final follow-up visit. Measures are pre-
sented as means + SD or percents unless otherwise speci-
fied. Measures are presented separately for each disease
category: Normal (all FPG values <100 mg/dL), IFG
(FPG>=100 mg/dL at any follow-up visit but no IGT/
T2DM), and IGT/T2DM (fasting glucose>125 mg/dL or 2
hr OGTT>=140 mg/dL at any visit). FPG of 100 mg/dL or
greater were classified as IFG, per the revised ADA criteria
for elevated fasting plasma glucose [12]. All subjects who
returned for at least one follow-up visit and did not have
IGT/T2DM at baseline were included in analyses of fol-
low-up measures. Logistic regression analyses were per-
formed to predict development of IGT/T2DM within 5
years (dichotomous outcome: 1 = IGT/T2DM, 0 = Normo-
glycemic) using baseline metabolic and physical meas-
ures. For inclusion into the regression models, the HOMA
= predictor variable was dichotomized as HOMA>2.24 vs
<=2.24 (the 75th percentile for baseline HOMA). For the
remaining predictors, the most extreme deciles in this
study population were used to dichotomize variables for
regression models (1 = highest risk decile, 0 = outside the
highest risk decile). For VO2max, deciles were determined
separately for males and females to account for gender dif-
ferences in oxygen consumption. Variables included in
the regression analyses include group (Standard or Inter-
vention), baseline age, gender, A1C, BMI, LDL, HDL, trig-
lycerides, albumin/creatinine ratio and VO2max.
Metabolic and physical variables that were found to be
significant in bivariate regression analyses were evaluated
as predictors in the subsequent multivariate analyses.
There were no significant differences between groups with
respect to baseline measures, changes over time, or inci-
dence of IGT/T2DM. Logistic regression analysis found
that study group was not associated with disease develop-
ment either alone or in multivariate models. Study group
was adjusted for in the analyses and given the similarities
between groups (showing no Intervention effect) the cur-
rent report presents results from a post-hoc analysis for
both groups combined in order to determine which risk
factors may potentially serve as early markers for IGT/
T2DM in this population.
Results
In this cohort of 388 individuals (22% male, age 46 + 11
years) at risk for type 2 diabetes, a total of 359 (93%)
returned for at least one follow-up visit, and 272 (70%)
completed the final 5-year assessment. Return rates were
similar between the two study groups.
Table 1 lists the prevalence of risk factors in this popula-
tion at baseline. Low VO2max was the most prevalent
abnormality, with 83% of the population considered
"high risk" based on age and gender-specific criteria (10).
Nine percent had baseline A1C values above 5.8%, seven
percent had A1C of 6.0% or greater, and more than one-
third (36%) had fasting glucose of 100 mg/dL or greater
in this population of individuals who were at risk for type
2 diabetes but who did not have IGT or T2DM at baseline.
Among those who had FPG<110 mg/dL, 32 people (9%)
had A1C>5.8% at baseline, while among those with base-
line FPG<100 mg/dL (the revised ADA criteria for normal
fasting plasma glucose), 17 people (7%) had A1C>5.8%.
Among the 27 people with elevated baseline A1C
(>=6.0%), 12 (44%) had FPG>=100 mg/dL and only 2
(7%) had FPG>=110 mg/dL.
Table 2 shows the baseline and final values for each vari-
able over the five-year follow-up period among those who
returned for at least one follow-up visit for the Standard
and Intervention groups combined. Disease status was
separated into three categories: 1) the "Normoglycemic"
Group includes those with all FPG values < 100 mg/dL, 2)
the IFG Group includes those who did not develop IGT/
T2DM but whose FPG was 100 mg/dL or greater at any
time during the five-year follow-up, and 3) the IGT/T2DM
Group includes those who developed IGT or T2DM at any
time over the five-year follow-up period. Among the 29
individuals who developed glucose intolerance, 17 devel-
oped IGT and an additional 12 developed T2DM over the
course of the trial.
Significant predictors of glucose intolerance in bivariate
regression analyses included A1C, BMI and VO2max. After
controlling for the other variables, A1C and BMI
remained significant, and VO2max was no longer a signif-
icant predictor of IGT/T2DM. The final regression model
included A1C (p < 0.0001) and BMI (p = 0.0179) as sig-
nificant predictors of IGT/T2DM within 5 years. Table 3
presents odds ratios, 95% confidence limits and p-values
for each variable in the final model, including BMI andDiabetology & Metabolic Syndrome 2009, 1:5 http://www.dmsjournal.com/content/1/1/5
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A1C (the other variables, including study group, did not
influence the odds of IGT/T2DM and were left out of the
final model). After controlling for BMI, the odds of devel-
oping disease within 5 years were 17.16 (95% CL: 6.169,
47.736) times greater for those with baseline A1C>=5.8%
as compared to those with A1C<5.8% (p < 0.0001).
Discussion
The results of our analysis of this study cohort indicated
that those individuals with higher baseline A1C values
(>= 5.8%) were at significantly higher risk for progression
to IGT and type 2 diabetes. While A1C levels have not
been routinely recommended as a measure of risk for
T2DM nor has A1C level been advocated as a tool to
screen for those at high risk, the current observations sup-
port the report of Miyazaki et al where elevated levels of
A1C in a cohort of Japanese subjects was strongly associ-
ated with increased risk of T2DM. Importantly, these
authors reported that both A1C and FPG are equally effec-
tive as diagnostic tools when compared to 2-h PG [13].
While the authors report an A1C level of 5.7% as the cut-
off for maximum sensitivity and specificity level, they also
found a significant increase in the prevalence of retinopa-
thy in their study population in those with A1C > 5.8%
(tenth decile) [13]. Also, data from the French cohort
study, an Epidemiological Study on the Insulin Resistance
Syndrome (DESIR), an A1C of 5.9% gave an optimal sen-
sitivity of 64% and specificity of 77% to predict diabetes
[14].
It is well established that the risk of diabetes complica-
tions increases with increasing A1C among individuals
with diabetes. Based on several recent studies, there is
increasing evidence that A1C may be associated with
adverse health outcomes, including cardiovascular disease
[15] and the metabolic syndrome [16], even among those
who do not have diagnosed diabetes. Blake, et al, report
that among women with no history of diabetes, A1C was
higher among those who experienced future cardiovascu-
lar events than those who did not, even among those with
A1C in the normal range (15). Findings by Osei, et al, sug-
gest that among African American individuals without
diabetes whose first-degree relatives have T2DM, A1C
between 5.7 and 6.2 (upper tertile) was associated with
reduced insulin action and other characteristics of the
metabolic syndrome (16). Corpus, et al, reports a higher
rate of adverse events among coronary patients without a
history of diabetes who had A1C between 6 and 7, com-
pared to those with A1C<6% [17]. Separate reports of
Selvin et al [18] evaluating data from the NHANES data-
base and Khaw et al [19] both found that increasing A1C
levels within the normal range were associated with a sig-
Table 1: Percent of total study population with high-risk values at baseline (N = 388)
Measure Value % of Subjects
FPG (mg/dL) >=110
>=100
5%
36%
SBP (mmHg) >=130 36%
DBP (mmHg) >=85 27%
Cholesterol (mg/dL) >=200 60%
LDL (mg/dL) >=130
>=100
48%
82%
HDL (mg/dL) <40 29%
Triglycerides (mg/dL) >150 51%
BMI (kg/m2)> = 3 0
>=27
36%
57%
A1C (%) >=6.0% 7%
Fasting Insulin (μU/mL) >23 2%
C-peptide (ng/mL) >4.0 8%
VO2max (mL/kg/min) high-risk score based on age and gender 83%Diabetology & Metabolic Syndrome 2009, 1:5 http://www.dmsjournal.com/content/1/1/5
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nificantly higher risk of cardiovascular disease (CVD).
Our findings contribute further evidence supporting that
A1C in the upper-normal or near-normal range among
those without diabetes is associated with negative health
outcomes, including both cardiovascular and metabolic
diseases.
The current study demonstrates that low cardiorespiratory
fitness (as defined by VO2max) is prevalent among indi-
viduals at high risk for T2DM (as defined by history of
GDM or family history of T2DM, and/or obesity, hyper-
tension and dyslipidemia,).
This study also confirms that high BMI, a risk factor tradi-
tionally associated with the metabolic syndrome, is
strongly associated with the development of both IGT and
T2DM. Furthermore, the trend of increasing A1C in our
population seen in the presence of declines in fasting glu-
cose over the course of the study period suggests that post-
prandial glucose values may be increasing. However this
Table 2: Baseline and final values (mean +SD or %) stratified by 5-year disease incidence among those who completed at least one 
follow-up visit (n = 359)
Normal
(n = 144)
IFG (without IGT/T2DM)
(n = 186)
IGT/T2DM
(n = 29)
Baseline Final Baseline Final Baseline Final
Metabolic
FPG
(mg/dL)
92 + 5 87 + 6 101 + 7 97 + 8 103 + 7 109 + 11
A1C
(%)
5.2 + 0.3 5.3 + 0.4 5.4 + 0.4 5.6 + 0.5 5.7 + 0.4 6.1 + 0.5
Insulin
(μU/mL)
5.8 + 4.4 5.8 + 3.5 7.7 + 5.2 8.0 + 5.1 11.0 + 7.3 11.4 + 6.8
C-peptide (ng/mL) 2.0 + 1.8 1.8 + 0.7 2.7 + 2.0 2.5 + 1.0 3.6 + 3.2 3.4 + 1.3
HOMA-IR
(units)
1.3 + 1.0 1.3 + 0.8 2.0 + 1.4 2.0 + 1.4 2.8 + 1.7 3.1 + 1.9
HDL
(mg/dL)
52 + 14 56 + 15 47 + 15 51 + 14 43 + 11 46 + 11
LDL
(mg/dL)
123 + 32 122 + 35 130 + 31 123 + 28 143 + 33 129 + 25
Triglyceride
(mg/dL)
130 + 70 126 + 70 173 + 128 158 + 98 210 + 93 206 + 92
A/C Ratio
(μg/mg)
5.3 + 3.8 8.8 + 9.6 7.5 + 16.6 17.2 + 78.1 7.5 + 16.3 16.3 + 47.4
Physical
BMI
(kg/m2)
26.7 + 5.3 27.7 + 5.8 30.0 + 6.1 30.9 + 6.1 31.0 + 6.5 31.4 + 5.6
SBP
(mmHg)
121 + 14 118 + 13 128 + 15 126 + 15 130 + 13 126 + 10
DBP
(mmHg)
78 + 8 75 + 8 82 + 8 80 + 8 81 + 9 77 + 7
VO2max
(ml/kg/min)
22.9 + 5.7 22.7 + 5.8 21.8 + 6.5 22.3 + 7.0 19.4 + 4.6 19.3 + 3.4Diabetology & Metabolic Syndrome 2009, 1:5 http://www.dmsjournal.com/content/1/1/5
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latter observation cannot be confirmed since only subjects
with FPG>=110 underwent OGTT in our study.
This community based diabetes risk assessment study
demonstrated that A1C value > 5.8% was a significant pre-
dictor of the development of IGT or T2DM within 5 years.
This study adds further strength to evidence supporting
use of integrated measures of glycemia as one tool in iden-
tifying those at highest risk for the development of IGT
and diabetes. The use of these simple screening measures
- if confirmed by other studies - would allow for identifi-
cation of the higher risk individuals in a community and
these individuals could then be targeted for diabetes pre-
vention programs utilizing both lifestyle and medical
therapies known to limit the risk of progression to diabe-
tes [20,21]. As Gerstein [22] notes, the increasing preva-
lence of diabetes indicates that the average A1C level of
the general population is likely increasing as well, and
because of the reported association between A1C and
CVD, a rise in CVD prevalence may occur in the future if
large-scale prevention efforts are not implemented. This
underscores the importance of public health efforts to
modify lifestyle with the goal of preventing T2DM and
CVD in populations at risk, and identifying those at risk at
an early point when such efforts could potentially prevent
the onset or progression of disease.
The community-based strategies included in this study
were designed to provide information and support in a
cost effective manner. In this population, a set of theory-
driven, low cost intervention activities did not result in
greater improvements over five years in those who
received the intervention compared to those who did not.
The reasons for this may be that such an intervention is
not as effective as in-person training and counseling ses-
sions. In addition, it is also possible that the semi-annual
group meetings and annual lab assessment and review did
not occur frequently enough to motivate changes in life-
style in this population.
In conclusion, the current study provides important infor-
mation regarding what level of intervention is needed in
order to motivate lifestyle changes in a population at risk
for T2DM. Further research is needed to determine if an
intervention of greater intensity would succeed in impact-
ing lifestyle and metabolic measures, and ultimately pre-
vent or delay T2DM in a population at risk. Importantly,
the current study demonstrates that a higher A1C level,
even within the normal range, is clearly associated with a
substantial increase in the risk of developing clinically sig-
nificant glucose intolerance within 5 years. Given this and
other studies, A1C should be more carefully assessed as a
predictor of diabetes in prospective clinical trails and,
pending the completion of such studies, should be con-
sidered as one measure used by clinicians when screening
individuals who are at risk for IGT and type 2 diabetes.
Our study supports increasing evidence of the importance
of A1C for risk assessment, screening and diagnostic pur-
poses as indicated recently by the International Expert
Committee [23].
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